Eli Lilly and Company (NYSE: LLY), a US-based global health care company, announced on Tuesday that it has signed a Joint Procurement Agreement with the European Commission to provide up to 220,000 doses of bamlanivimab and etesevimab to treat confirmed COVID-19 in patients aged 12 years and older who do not need supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.
The contract helps to provide access to treatments by allowing participating countries in the European Union and European Economic Area to buy the products directly from Lilly, subsequent to the national approval for emergency use, or marketing authorisation at the European Union level. Quantities purchased are likely to vary based on local requirements as determined by participating countries.
Preclinical data from the labs have indicated that bamlanivimab and etesevimab administered together retain neutralisation activity compared to COVID variants presently in circulation in various countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, presently more than 95% of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT